CSBio CSBio

X
[{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syngene International extends Long Term Research Collaboration with Bristol Myers Squibb until 2030","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Syngene International Limited"},{"orgOrder":0,"company":"Excelra","sponsor":"HotSpot Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Excelra"},{"orgOrder":0,"company":"Aurigene","sponsor":"Olema Oncology","pharmaFlowCategory":"D","amount":"$438.0 million","upfrontCash":"$8.0 million","newsHeadline":"Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Aurigene"},{"orgOrder":0,"company":"Bugworks","sponsor":"Cytecare Cancer Hospitals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bugworks Research Inc. and Cytecare Cancer Hospitals Announce Collaboration to Accelerate the Development of Cutting-Edge Immuno-Oncology Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Bugworks"},{"orgOrder":0,"company":"Aurigene","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership With EQRX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Aurigene"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The partnership between leading drug discovery start-up and leading cancer hospital paves way for the development of novel Immuno-oncology drugs that can be effective in wider patient populations.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cytecare Cancer Hospitals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the collaboration agreement, Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: EQRx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 05, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Olema and Aurigene will jointly direct preclinical work and, if successful, Olema will lead clinical development as well as regulatory and commercial activities.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Olema Oncology

            Deal Size: $438.0 million Upfront Cash: $8.0 million

            Deal Type: Collaboration June 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            HotSpot Therapeutics plans to deploy data from Excelra’s flagship product GOSTAR toward select protein targets to augment its allosteric inhibitor candidate pipeline.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: HotSpot Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutical development.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Bristol Myers Squibb

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY